Bogart Wealth LLC Has $10.73 Million Holdings in Insulet Corporation $PODD

Bogart Wealth LLC cut its position in Insulet Corporation (NASDAQ:PODD) by 12.0% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 34,165 shares of the medical instruments supplier’s stock after selling 4,658 shares during the period. Bogart Wealth LLC’s holdings in Insulet were worth $10,734,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in PODD. GAMMA Investing LLC boosted its position in Insulet by 4.3% in the first quarter. GAMMA Investing LLC now owns 2,529 shares of the medical instruments supplier’s stock valued at $664,000 after buying an additional 105 shares in the last quarter. Wealth Enhancement Advisory Services LLC boosted its position in Insulet by 13.9% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 3,028 shares of the medical instruments supplier’s stock valued at $795,000 after buying an additional 370 shares in the last quarter. Exchange Traded Concepts LLC boosted its position in Insulet by 225.4% in the first quarter. Exchange Traded Concepts LLC now owns 1,552 shares of the medical instruments supplier’s stock valued at $408,000 after buying an additional 1,075 shares in the last quarter. Janney Montgomery Scott LLC boosted its position in Insulet by 2.9% in the first quarter. Janney Montgomery Scott LLC now owns 5,405 shares of the medical instruments supplier’s stock valued at $1,419,000 after buying an additional 154 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its position in Insulet by 75.6% in the first quarter. QRG Capital Management Inc. now owns 2,030 shares of the medical instruments supplier’s stock valued at $533,000 after buying an additional 874 shares in the last quarter.

Insider Activity at Insulet

In related news, SVP Laetitia Cousin sold 797 shares of the stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $348.81, for a total value of $278,001.57. Following the transaction, the senior vice president directly owned 3,890 shares in the company, valued at $1,356,870.90. This represents a 17.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Prem Singh sold 687 shares of the company’s stock in a transaction that occurred on Monday, September 8th. The shares were sold at an average price of $347.49, for a total transaction of $238,725.63. Following the completion of the sale, the senior vice president directly owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.39% of the company’s stock.

Insulet Trading Up 0.7%

Shares of NASDAQ PODD opened at $318.59 on Monday. The company’s 50 day simple moving average is $326.22 and its 200 day simple moving average is $302.53. Insulet Corporation has a fifty-two week low of $226.50 and a fifty-two week high of $353.50. The firm has a market capitalization of $22.43 billion, a P/E ratio of 96.84, a P/E/G ratio of 2.66 and a beta of 1.40. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $1.17 earnings per share for the quarter, beating the consensus estimate of $0.92 by $0.25. Insulet had a net margin of 10.01% and a return on equity of 23.78%. The business had revenue of $649.10 million for the quarter, compared to analyst estimates of $612.31 million. During the same period in the prior year, the business posted $0.55 earnings per share. Insulet’s revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, analysts predict that Insulet Corporation will post 3.92 EPS for the current year.

Analyst Ratings Changes

A number of research firms have commented on PODD. JPMorgan Chase & Co. boosted their price target on shares of Insulet from $340.00 to $415.00 and gave the company an “overweight” rating in a research report on Friday, September 12th. Citigroup reiterated a “buy” rating on shares of Insulet in a research report on Tuesday, July 8th. Rothschild & Co Redburn upped their target price on shares of Insulet from $350.00 to $370.00 and gave the stock a “buy” rating in a research report on Friday, October 3rd. Royal Bank Of Canada upped their target price on shares of Insulet from $350.00 to $365.00 and gave the stock an “outperform” rating in a research report on Friday, October 10th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of Insulet in a research report on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $348.05.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.